TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP) today reported its financial results for the three and twelve-month period ended December 31, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). 2019 Highlights Amended and restated (“A&R”) partnership agreement with Aytu Bioscience (“Aytu”) becomes fully functional which should allow for accele

READ MORE: https://www.businesswire.com/news/home/20200304005076/en/Acerus-Reports-Fourth-Quarter-Full-Year-2019/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhB8bDel5XZmwWFQYQPHxx__rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3kCXJZE-1b1nXn968wYfofVLkaZDLiczsahzEklD3R10Q==